AEON Biopharma (AEON) Debt Ratio (2021 - 2026)

AEON Biopharma (AEON) posted Debt Ratio of 6.22 for Q4 2025, up 218.76% sequentially from 1.95 in Q3 2025, and up 67.27% YoY from 3.72 in Q4 2024.

AEON Biopharma (AEON) Debt Ratio (2021 - 2026) Analysis & Trends

AEON Biopharma has reported Debt Ratio for 4 years, with the latest figure at 6.22 in Q4 2025.

Quarterly Debt Ratio rose 67.27% year-over-year to 6.22 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 6.22 (up 67.27% YoY) and the FY2025 annual result came in at 6.22, up 67.27% from the prior year.
Debt Ratio advanced to 6.22 in Q4 2025 per AEON's latest filing, from 1.95 in the prior quarter.
Over five years, Debt Ratio peaked at 6.22 in Q4 2025 and troughed at 0.0 in Q2 2021.
A 4-year average of 2.01 and a median of 1.82 in 2024 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 67.27% in 2025, down 48.47% in 2025.
Over 4 years, Debt Ratio stood at 0.0 in 2021, then soared by 17022492.28% to 2.15 in 2022, then jumped by 73.34% to 3.72 in 2024, then jumped by 67.27% to 6.22 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 6.22, 1.95, and 1.3 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	AEON Biopharma	9.71 Mn	6.28 Mn	-	0.30

Download Data